Last edition
News about "Respiratory Syncytial Virus (RSV)"
US FDA Accepts sBLA for ENFLONSIA to Expand RSV Indication
US Food and Drug Administration (FDA) and European Medicines Agency (EMA) accept applications for ENFLONSIA (clesrovimab-cfor) to expand RSV protection for high-risk children under 2 years of age during their second Respiratory Syncytial Virus (RSV) season.
Respiratory Syncytial Virus (RSV) | 07/08/2026 | By News Bureau
Clover Biopharmaceuticals Completes Initial Enrollment in Phase II Trial of RSV Combination Vaccines
The Australia-based Phase II study is evaluating Clover’s protein-based combination vaccine candidates SCB-1022 and SCB-1033 targeting RSV, hMPV and PIV3 in older adults, using its proprietary Trimer-Tag technology.
Respiratory Syncytial Virus (RSV) | 12/01/2026 | By News Bureau | 615
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy